Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis

References

• Abufaraj M, Iwata T, Kimura S, et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol. 2021;79(1):44–53.
   PubMed Web of Science ®Google Scholar
• Mathieu R, Korn SM, Bensalah K, et al. Cytoreductive radical prostatectomy in metastatic prostate cancer: does it really make sense? World J Urol. 2017;35(4):567–577.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018;1(1):46–53.
   PubMed Web of Science ®Google Scholar
• Preisser F, Mazzone E, Nazzani S, et al. Comparison of perioperative outcomes between cytoreductive radical prostatectomy and radical prostatectomy for nonmetastatic prostate cancer. Eur Urol. 2018;74(6):693–696.
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–282.
   PubMed Web of Science ®Google Scholar
• Kluth LA, Shariat SF, Kratzik C, et al. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol. 2014;32(3):669–676.
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–479.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Kuzma M, Kliment J. Metastasis-free survival as a new endpoint in castration–resistant prostate cancer. Bratisl Lek Listy. 2020;121(6):411–414.
   PubMed Web of Science ®Google Scholar
• Xie W, Regan MM, Buyse M, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097–3104.
   PubMed Web of Science ®Google Scholar
• van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285–299.
   PubMed Web of Science ®Google Scholar
• Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313–2324.
   PubMed Web of Science ®Google Scholar
• Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
   PubMed Web of Science ®Google Scholar
• Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European study group on neoadjuvant treatment of prostate cancer. Eur Urol. 2000;38(6):706–713.
   PubMed Web of Science ®Google Scholar
• Prezioso D, Lotti T, Polito M, et al. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int. 2004;72(3):189–195.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112–116.
   PubMed Web of Science ®Google Scholar
• Yee DS, Lowrance WT, Eastham JA, et al. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int. 2010;105(2):185–190.
   PubMed Web of Science ®Google Scholar
• Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90(6):561–566.
   PubMed Web of Science ®Google Scholar
• Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170(3):791–794.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Festuccia C, Galatioto GP, et al. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology. 2007;70(4):728–733.
   PubMed Web of Science ®Google Scholar
• Selli C, Montironi R, Bono A, et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol. 2002;55(7):508–513.
   PubMed Web of Science ®Google Scholar
• Dalkin BL, Ahmann FR, Nagle R, et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 1996;155(4):1357–1360.
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology. 1997;49(3A Suppl):56–64.
   PubMed Web of Science ®Google Scholar
• Bullock MJ, Srigley JR, Klotz LH, et al. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol. 2002;26(11):1400–1413.
   PubMed Web of Science ®Google Scholar
• van der Kwast TH, Têtu B, Candas B, et al. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53(3):523–529.
   PubMed Web of Science ®Google Scholar
• Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166(2):500–506. discussion 506–507
   PubMed Web of Science ®Google Scholar
• Hugosson J, Abrahamsson PA, Ahlgren G, et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol. 1996;29(4):413–419.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol. 2018;199(4):990–997.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Eggener SE, Hernandez AV, et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65(4):675–680.
   PubMed Web of Science ®Google Scholar
• Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010;58(5):687–700.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kattan MW, Vickers AJ, et al. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5(10):1555–1584.
   PubMed Web of Science ®Google Scholar
• Karam JA, Lotan Y, Roehrborn CG, et al. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007;67(6):614–622.
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. Jama. 1999;281(17):1591–1597.
   PubMed Web of Science ®Google Scholar
• Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int. 2008;101(12):1513–1518.
   PubMed Web of Science ®Google Scholar
• Bandini M, Fossati N, Gandaglia G, et al. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Rev Clin Pharmacol. 2018;11(4):425–438.
   PubMed Web of Science ®Google Scholar
• Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the national cancer data base (NCDB). Ann Surg. 2018;268(4):591–601.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23(Suppl 10):x231–x236.
   PubMed Web of Science ®Google Scholar
• McKay RR, Montgomery B, Xie W, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018;21(3):364–372.
   PubMed Web of Science ®Google Scholar
• Mori K, Mostafaei H, Pradere B, et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25(11):1892–1900.
   PubMed Web of Science ®Google Scholar
• McKay RR, Ye H, Xie W, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol. 2019;37(11):923–931.
   PubMed Web of Science ®Google Scholar
• Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240.
   PubMed Web of Science ®Google Scholar
• Montgomery B, Tretiakova MS, Joshua AM, et al. Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res. 2017;23(9):2169–2176.
   PubMed Web of Science ®Google Scholar